Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status approved; investigational
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 0074-1658; 0074-4637; 0074-9036; 0143-9624; 65162-823; 65862-936; 70121-1035; 43598-565; 55150-213; 67457-379; 66499-0019; 16729-311; 43598-562; 55150-215; 68382-331; 65862-938; 67457-692; 69452-147; 10888-8103; 10888-8104; 11014-0334; 48943-0033; 58032-1001; 68513-1054; 49483-689; 55150-212; 68382-330; 69452-145; 70121-1033; 70121-1034; 10888-8102; 14474-021; 0143-9625; 49483-687; 65862-937; 11014-0048; 55111-663; 70121-1036; 58272-192; 0074-9037; 43598-563; 49483-688; 55111-665; 63629-2452; 67457-380; 16729-310; 25000-017; 0143-9596; 55150-214; 63629-2453; 65162-822; 67457-389; 69452-146; 25000-014; 43598-564; 55111-664; 65162-824; 11014-0053; 25000-012
UNII 6702D36OG5
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Metabolic disorder14.11.01.0010.001962%Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.0070.002943%Not Available
Adverse event08.06.01.0100.188360%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.0030.445392%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Diabetic complication14.07.03.002; 05.07.03.0020.001962%Not Available
Infarction24.04.02.0170.188360%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.0040.002943%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Poisoning12.03.01.004--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Unevaluable event08.01.03.0510.072597%Not Available
Arterial occlusive disease24.04.02.0210.002943%Not Available
Hepatic enzyme abnormal13.03.04.026--Not Available
Chronic kidney disease20.01.03.0170.027469%
Adverse reaction08.06.01.018--Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.016--
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene